Patient Recruitment
& Identification
Identifying Early Rare Disease Patients Through “Real-Patient-Evidence” Data
Many patient identification strategies rely on AI-generated probabilities, digital signals, or estimated cohorts. But a probability is not a real patient. We have a fundamentally different approach.
subrosa OmicsAI’s clinical patient identification programs are built on our proprietary global repositories of rare disease patients - one of the world’s largest - genetically confirmed, sourced from real clinical diagnostics, not from algorithmic predictions.
Our rare disease genetics scientists from offices across US, Europe, China, APAC, CIS, GCC and LATAM run the clinical studies aligned with your medical team. By recruiting new cohorts in a unique way, patients are detected where no other organization can recruit them, years earlier than today’s standards. Hitting a precisely calculated success rate. Not estimated, data-driven calculated. Proven in more than 40 worldwide published programs.
Identification without access to patients is only one slide in a deck. Holistic patient access by subrosa accelerates outcomes. We keep both physicians & patients engaged across the full clinical journey through sustained communication. Ensuring that patients receive treatment & stay adherent – even in markets without product authorization via Early Access, Compassionate Use and Named Patient Programs.
Illuminating the unseen, no rare disease patient should be left behind
Finding Rare Disease Patients Additionally Through …..
Omnichannel-Communication: 42health’s field, remote or hybrid teams find patients through communication with "out of reach" HCPs, educating their disease awareness for non-genetic (27%) or genetic-based (63%) rare disease indications.
Explore 42health →Face recognition: in addition to the clinical symptoms and recorded images of subrosa OmicsAI’s patient database, we are developing a global dataset of rare disease facial characteristics using images, crowdsourced from clinicians, patients, patient organizations, labs, researchers and screening programs. This real-world data - mapped to HPO terms - is not a big breakthrough in patient identification but will bring the one or other add-on patient and may speed-up our clinical programs.
Like CROs: we find patient populations through our intensive global rare disease-KOL-Network in the “Centers of Excellence” and collaboration with Patient Advocacy Organizations and databases of authorities
Healing Wings Foundation →Clinical Patient Identification Programs
subrosa OmicsAI identifies undiagnosed and underdiagnosed rare-disease patients by combining genomic intelligence,
phenotype-first screening, patient-data structures, expert medical interpretation and global access networks.
subrosa OmicsAI Services
Transforming the way rare genetic diseases are identified.
- Early Detection of Genetic Diseases
- Validating Target Populations with Real-World Prevalence Data
- OENI Study* Program
- Multi-Omics Gene Database Technologies
- Global Patient Recruitment Program
- Patient Registry & Support Program
- Clinical Trial Management
- Developing Predictive Algorithms for Early Diagnosis Tools
- Global Patient Identification Program
- Patient Registry & Support Program
- Reaching Undiagnosed Patient Populations
- Go-to-Market-Strategies/Commercialization
Identifying Rare. Precisely. Early. Globally.
* OENI = Observational Epidemiological Non-Interventional Study
subrosa OmicsAI — by the numbers
Faster drug development, precise patient identification — driven by hard data, not estimates.
Prof. Dr. Arndt Rolfs
One of the world’s leading rare disease specialists · Advisor to FDA & EMA
From identification to impact
Our focus is patient identification & recruitment — but it’s only where the journey begins.
Finding a patient is the first step, not the destination. Identifying rare disease patients through real-patient-evidence is where subrosa OmicsAI begins — but a confirmed patient only creates value when they reach the right therapy, stay on it, and are supported throughout their journey.
Patient Access
Once patients are identified, subrosa’s holistic patient access accelerates and expands access for patients regardless of where they live — from clinical study recruitment and disease awareness to securing treatment, supporting adherence and supplying patients even before market authorization. Beginning-to-end, no patient left behind.
Explore Patient Access →Clinical Operations
From preclinical evidence to clinical proof-of-concept. subrosa designs, coordinates and delivers services across the critical stages from early scientific development to clinical trial execution — shortening timelines and de-risking assets at the transition into human studies. A capital-efficient globalization platform that makes early-stage and rare disease assets investable, approvable and competitive.
Explore Clinical Operations →Medical Solutions
We help convert approvals into adoption and revenue. subrosa’s medical affairs services ensure therapies are understood and used appropriately: unbiased medical information, KOL engagement, new patient populations and real-world evidence that meet regulatory requirements and deliver value to patients.
Explore Medical Solutions →Identification, access and medical impact — one connected platform, one accelerated path.
subrosa covers the full lifecycle — beyond the patient journey, our solutions span Go-to-Market, Commercial Engagements, Licensing & Funds, and Talent & HR.
Built for speed
We don’t promise what we might not be able to keep.